379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)
Year: 2008
Type: conference-abstract
Authors: R. Kurzrock, S. Sherman, D. Hong, C. Ng, J. Frye, L. Janisch, M.J. Ratain, R. Salgia
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2007193634